Conatus Pharmaceuticals (CNAT) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts CNAT Hot Sheet
Join SI Premium – FREE
Conatus Pharmaceuticals (NASDAQ: CNAT) reported Q3 EPS of ($0.13), $0.08 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $9.6 million versus the consensus estimate of $16.06 million.
For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
